Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIGIT class of checkpoint inhibitors fails with Keytruda

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 16, 2024 11:20am

116 Views

Post# 36182643

RE:RE:RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda

At Genentech, Mellman oversaw the discovery and development of Tecentriq — the checkpoint inhibitor that is central to Roche’s oncology portfolio – Lunsumio, and the company’s anti-TIGIT program. ONCY has been instrumental in revealing how pelareorep is synergistic with PD-(L)1 checkpoint inhibitors, such as with Roche's PD-L1 Tecentriq.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing